Economics

[malfeasance]

For example, I have been following Pharmasset, Inc. (VRUS) – Gilead Sciences, Inc. - for over a year. In that time, their share price has risen from $30 to over $125!!!

Ouch! It's .0016 now . . . that's less than a fifth of a penny.

 

[Michael Scally MD]

Ouch! It's .0016 now . . . that's less than a fifth of a penny.

A bit late to the ballgame.

[2011] Gilead bets $11 billion on hepatitis in Pharmasset deal
Gilead bets $11 billion on hepatitis in Pharmasset deal

Gilead Sciences Inc GILD.O struck a deal to buy biotechnology company Pharmasset Inc VRUS.O for about $11 billion in a huge and risky bet on the next generation of hepatitis C treatments.

Gilead, the world’s largest maker of HIV drugs, will pay $137 per share for each Pharmasset share, an 89 percent premium for a company with no significant marketed products.

Pharmasset shares had already more than tripled in the past year based on the potential of its experimental hepatitis C medicines to create a new standard of care for the 180 million people worldwide infected with the serious liver disease.

 

[AnaboliClem]

Any UK Investors having their S&S ISA's pop this week? Feels good man!